In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus, contributing significantly to the morbidity and mortality of the affected individuals. However, significant differences in clinical approaches to lupus nephritis management still persist.
Read Article
Urvi Zala is a PGY-2 Internal Medicine resident at Loyola Medicine MacNeal Hospital, Illinois. She completed medical school in India, where an early clinical encounter with a delayed diagnosis of juvenile myositis sparked her interest in rheumatology. She plans to pursue a rheumatology fellowship and has research interests in lupus—particularly lupus nephritis—and vasculitis. Her work, including a network meta-analysis of calcineurin inhibitors in lupus nephritis, has been presented at ACR 2025.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
